3 active not recruiting, 2 completed, 1 recruiting. 5 Phase 2, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Active not recruiting 3, Completed 1, Recruiting 1 |
| Phase 1 | 1 | Active not recruiting 1 |
| Phase 3 | 1 | Completed 1 |
Follow Stage IV Gallbladder Cancer AJCC v8: new trials by email Literature Review of Stage IV Gallbladder Cancer AJCC v8 trials Research Report on Stage IV Gallbladder Cancer AJCC v8
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Alternating Chemo-immunotherapy and FGFR Inhibitor for FGFR-positive Biliary or Cholangiocarcinoma Biospecimen Collection, Cisplatin, Computed Tomography - Locally Advanced Ampulla of Vater Carcinoma, Locally Advanced Biliary Tract Carcinoma | Phase 2 | Recruiting | Ohio State University Comprehensive Cancer Center | 29 | 2026-11-01 | 2026-09-10 |
| Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH Treatment Trial) Binimetinib, Biopsy Procedure, Biospecimen Collection - Advanced Biliary Tract Carcinoma, Advanced Gallbladder Carcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 17 | 2024-02-09 | 2026-10-19 |
| Testing A New Combination of Anti-cancer Immune Therapies, Atezolizumab and CDX-1127 (Varlilumab) With or Without the Addition of a Third Anti-cancer Drug, Cobimetinib, for Advanced-Stage Biliary Tract Cancer Atezolizumab, Biopsy, Biospecimen Collection - Metastatic Distal Bile Duct Adenocarcinoma, Metastatic Gallbladder Carcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 57 | 2021-12-15 | 2025-05-23 |
| Testing the Combination of New Anti-cancer Drug Peposertib With Avelumab and Radiation Therapy for Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies Avelumab, Biopsy Procedure, Biospecimen Collection - Locally Advanced Malignant Solid Neoplasm, Locally Advanced Unresectable Cholangiocarcinoma | Phase 1 / Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 103 | 2020-04-07 | 2026-10-02 |
| Trifluridine/Tipiracil and Irinotecan for the Treatment of Advanced Refractory Biliary Tract Cancer Irinotecan, Irinotecan Hydrochloride, Trifluridine and Tipiracil Hydrochloride - Advanced Bile Duct Carcinoma, Advanced Gallbladder Carcinoma | Phase 2 | Completed | Mayo Clinic | 28 | 2019-10-18 | 2023-08-09 |
| Gemcitabine Hydrochloride and Cisplatin With or Without Nab-Paclitaxel in Treating Patients With Newly Diagnosed Advanced Biliary Tract Cancers Cisplatin, Gemcitabine Hydrochloride, Nab-paclitaxel - Stage III Distal Bile Duct Cancer AJCC v8, Stage III Gallbladder Cancer AJCC v8 | Phase 3 | Completed | SWOG Cancer Research Network | 452 | 2019-02-07 | 2026-01-12 |
Gallbladder Neoplasms (6) · Cholangiocarcinoma (5) · Bile Duct Neoplasms (1) · Klatskin Tumor (1) · Neoplasm Metastasis (1)
Biliary Tract Diseases (6) · Biliary Tract Neoplasms (6) · Digestive System Diseases (6) · Digestive System Neoplasms (6) · Gallbladder Diseases (6) · Neoplasms (6) · Neoplasms by Site (6) · Adenocarcinoma (5) · Carcinoma (5) · Neoplasms by Histologic Type (5) · Neoplasms, Glandular and Epithelial (5) · Bile Duct Diseases (1) · Neoplastic Processes (1) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1)
Specimen Handling (4) · Biopsy (3) · Magnetic Resonance Spectroscopy (3) · 1,2-diaminocyclohexaneplatinum II citrate (2) · Cisplatin (2) · Disulfides (2) · Gemcitabine (2) · Immunoglobulin G (2) · Platinum (2) · 130-nm albumin-bound paclitaxel (1) · Albumin-Bound Paclitaxel (1) · Fluorouracil (1) · Irinotecan (1) · Leucovorin (1) · Oxaliplatin (1)
National Cancer Institute (NCI) (3) · Mayo Clinic (1) · Ohio State University Comprehensive Cancer Center (1) · SWOG Cancer Research Network (1)
United States (6)
Amit Mahipal (1) · Ardaman Shergill (1) · Kristen R Spencer (1) · Nilofer S Azad (1) · Rachna Shroff (1) · Sameek Roychowdhury, MD, PhD (1)
U10CA180821 (1), U10CA180888 (1), UM1CA186644 (1), UM1CA186691 (1), UM1CA186716 (1)